DaVita Inc. (NYSE:DVA) Stake Lifted by Redwood Investment Management LLC

Redwood Investment Management LLC increased its position in DaVita Inc. (NYSE:DVA) by 4.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,360 shares of the company’s stock after buying an additional 402 shares during the quarter. Redwood Investment Management LLC’s holdings in DaVita were worth $1,690,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Transcendent Capital Group LLC purchased a new stake in shares of DaVita during the third quarter valued at $25,000. Blue Trust Inc. boosted its position in shares of DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares during the period. Family Firm Inc. acquired a new position in shares of DaVita in the 2nd quarter valued at $43,000. Friedenthal Financial acquired a new position in shares of DaVita in the 2nd quarter valued at $48,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of DaVita in the 2nd quarter valued at $68,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on DVA shares. Truist Financial raised their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. UBS Group raised their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Finally, Barclays raised their price target on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $161.80.

Insider Activity at DaVita

In related news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.00% of the stock is currently owned by corporate insiders.

DaVita Price Performance

Shares of NYSE:DVA opened at $161.39 on Friday. DaVita Inc. has a 1-year low of $103.40 and a 1-year high of $169.51. The firm has a market capitalization of $13.23 billion, a PE ratio of 17.41, a PEG ratio of 0.93 and a beta of 0.90. The business’s 50 day moving average is $158.65 and its 200-day moving average is $149.93. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same period in the prior year, the firm earned $2.85 EPS. DaVita’s quarterly revenue was up 4.6% compared to the same quarter last year. Sell-side analysts predict that DaVita Inc. will post 9.71 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.